Cerity Partners LLC Has $10.91 Million Holdings in Sanofi (NASDAQ:SNY)

Cerity Partners LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 62.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,726 shares of the company's stock after buying an additional 75,698 shares during the quarter. Cerity Partners LLC's holdings in Sanofi were worth $10,910,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Invesco Ltd. boosted its holdings in shares of Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock worth $581,619,000 after acquiring an additional 408,752 shares in the last quarter. Bank of America Corp DE boosted its stake in Sanofi by 3.8% in the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after purchasing an additional 441,637 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Boston Partners increased its stake in shares of Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Sanofi by 10.8% in the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after buying an additional 369,530 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SNY shares. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Finally, Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Price Performance

SNY opened at $48.55 on Tuesday. The company has a fifty day moving average price of $49.93 and a two-hundred day moving average price of $52.13. The firm has a market capitalization of $119.07 billion, a PE ratio of 17.34, a P/E/G ratio of 1.11 and a beta of 0.48. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period in the previous year, the firm earned $1.78 earnings per share. The firm's quarterly revenue was down 11.0% compared to the same quarter last year. As a group, analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.